肾小球高滤过作为CKD治疗靶点
综述指出肾小球高滤过是CKD早期病理生理表现,可表现为绝对高滤过(高GFR)或相对高滤过(GFR正常或降低)。现有肾脏保护药物均诱导早期GFR下降,可能反映高滤过逆转。识别高滤过可提供早于白蛋白尿或GFR下降的干预窗口,但缺乏高敏感特异性诊断方法,仅绝对高滤过(如早期糖尿病肾病)易识别。
要点
- 肾小球高滤过是CKD早期可干预靶点,现有肾脏保护药物早期GFR下降可能反映其逆转。
- 单肾单位高滤过可表现为绝对高滤过(高GFR)或相对高滤过(GFR正常或降低)。
- 缺乏高敏感特异性诊断方法,仅绝对高滤过(如早期糖尿病肾病)易识别。
核心结论
- 肾小球高滤过是CKD风险的早期指标,识别它可提供早于当前标准的干预窗口。
- 现有肾脏保护药物诱导的早期GFR下降可能代表高滤过逆转。
研究设计与样本
- 综述,检索范围未报告。
主要发现
- 单肾单位高滤过可导致绝对高滤过(高GFR)或相对高滤过(GFR正常或降低)。
- 代偿性高滤过增加肾小球毛细血管压力及肾小球和足细胞体积,驱动足细胞丢失、白蛋白尿和近端小管过载,促进CKD进展。
- 从RAS阻断剂到MR阻断剂、SGLT2抑制剂、托伐普坦,所有临床使用的肾脏保护药物均诱导早期GFR下降,被认为代表高滤过逆转。
- 目前无高敏感特异性诊断方法识别单肾单位高滤过,仅当导致明显绝对高滤过时(如早期糖尿病肾病肾单位质量尚存)可识别。
关键数值与推荐
- 绝对高滤过定义为高GFR,相对高滤过定义为GFR正常或降低(因肾单位丢失)。
- 无高敏感特异性诊断方法识别单肾单位高滤过,仅绝对高滤过(如早期糖尿病肾病)可识别。
临床怎么用
- 肾小球高滤过可作为CKD早期干预靶点,现有肾脏保护药物早期GFR下降可能反映高滤过逆转。
- 识别高滤过(尤其绝对高滤过)可提供早于白蛋白尿或GFR下降的干预窗口。
局限性
- 缺乏高敏感特异性诊断方法识别单肾单位高滤过。
- 仅绝对高滤过(如早期糖尿病肾病肾单位质量尚存时)易识别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The global burden of chronic kidney disease (CKD) is high and increasing. Early diagnosis and intervention are key to improve outcomes. Single-nephron glomerular hyperfiltration is an early pathophysiologic manifestation of CKD that may result in absolute glomerular hyperfiltration, i.e. a high glomerular filtration rate (GFR), or be associated with normal or low GFR because of nephron loss (relative glomerular hyperfiltration). Even though compensatory glomerular hyperfiltration may contribute to maintain kidney function after the loss of kidney mass, the associated increased glomerular capillary pressure and glomerular and podocyte size drive podocyte loss, albuminuria and proximal tubular overload, contributing to CKD progression. In this regard, all kidney protective drugs in clinical use so far, from renin-angiotensin system blockers to mineralocorticoid receptor blockers to sodium-glucose co-transporter 2 inhibitors to tolvaptan, induce an early dip in glomerular filtration that is thought to represent reversal of hyperfiltration. As glomerular hyperfiltration may be present early in the course of kidney disease, its recognition may provide an effective intervention window that may predate current criteria based on high albuminuria or loss of GFR. Nevertheless, there is no diagnostic method with high sensitivity and specificity to identify single-nephron glomerular hyperfiltration, except when it leads to obvious absolute glomerular hyperfiltration, as observed in the early stages of diabetic kidney disease when nephron mass is still preserved. We now review the concept of glomerular hyperfiltration as an indicator of CKD risk, including definitions, challenges in diagnosis and evaluation, underlying pathophysiological mechanisms, potential therapeutic approaches and unanswered questions.
引用
- Kanbay M, Copur S, Bakir CN, et al. Glomerular hyperfiltration as a therapeutic target for CKD. Nephrol Dial Transplant. 2024. PMID: 38308513. doi:10.1093/ndt/gfae027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。